- Home
- WT vs TARS Comparison
WT vs TARS Comparison
Compare WT & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WT | TARS |
|---|---|---|
| Founded | 1985 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.7B |
| IPO Year | 2011 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WT | TARS |
|---|---|---|
| Price | $19.25 | $55.66 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 6 |
| Target Price | $17.67 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 3.2M | 1.2M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.74% | N/A |
| EPS Growth | ★ 127.27 | 48.21 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $493,753,000.00 | $451,360,000.00 |
| Revenue This Year | $35.04 | $56.43 |
| Revenue Next Year | $8.68 | $30.19 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 15.43 | ★ 146.71 |
| 52 Week Low | $10.69 | $38.51 |
| 52 Week High | $20.18 | $85.25 |
Technical Indicators
Market Signals| Indicator | WT | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 38.14 |
| Support Level | $18.50 | N/A |
| Resistance Level | $19.71 | $67.14 |
| Average True Range (ATR) | 0.74 | 4.56 |
| MACD | 0.18 | -0.89 |
| Stochastic Oscillator | 73.73 | 0.77 |
Price Performance
Historical ComparisonAbout WT WisdomTree Inc.
WisdomTree Inc is a financial innovator, offering a diverse suite of Exchange-traded products (ETPs), models and solutions, private market investments and digital asset-related products. It also offers digital products and services related to tokenized real world assets and stablecoins, including tokenized mutual funds (Digital Funds), as well as its institutional platform, WisdomTree Connect, and blockchain-native digital wallet, WisdomTree Prime. The company's products are distributed across various asset management industry channels, including banks, brokerage firms, registered investment advisers, institutional investors, private wealth managers and online brokers. The majority of the company's revenue is generated from advisory fees earned from ETPs.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.